---
title: "Keymed Biosciences swings to FY26 H1 profit of RMB 1.22 billion; revenue rises 24% to RMB 617.07 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296362971.md"
description: "Keymed Biosciences reported a swing to an IFRS profit of RMB 1.22 billion for FY26 H1, with revenue rising 24% to RMB 617.07 million. Product revenue more than doubled to RMB 393 million, driven by Kangyueda's inclusion in China’s National Reimbursement Drug List. Collaboration revenue reached RMB 224 million from an AstraZeneca milestone payment. Other income and gains surged to RMB 1.71 billion, primarily from the disposal of equity interest in Ouro Medicines."
datetime: "2026-08-19T13:24:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296362971.md)
  - [en](https://longbridge.com/en/news/296362971.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296362971.md)
generator: "portal-rs"
---

# Keymed Biosciences swings to FY26 H1 profit of RMB 1.22 billion; revenue rises 24% to RMB 617.07 million

-   Keymed Biosciences posted IFRS profit of RMB 1.22 billion, swinging from a loss, as revenue rose 24% to RMB 617.07 million. \* Product revenue more than doubled to RMB 393 million, driven by Kangyueda’s inclusion in China’s National Reimbursement Drug List from Jan. 1, 2026. \* Collaboration revenue reached RMB 224 million, mainly from a milestone payment under the AstraZeneca license for CMG901/AZD0901. \* Other income and gains climbed to RMB 1.71 billion, primarily from disposal and realization of the equity interest in Ouro Medicines. \* Cash and equivalents, time deposits, and financial and other investments increased 65% to RMB 3.24 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12290998), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [02162.HK](https://longbridge.com/en/quote/02162.HK.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumors](https://longbridge.com/en/news/296571352.md)
- [Aikobio’s AK0406 flu prevention drug wins China IND clearance for clinical trials](https://longbridge.com/en/news/296204995.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)
- [Kuaishou Technology: AI-driven growth and Kling AI's surge fueled Q2 profit and revenue gains amid macro headwinds](https://longbridge.com/en/news/296364665.md)
- [Sino Biopharma rebrands global operations under SBP Group identity](https://longbridge.com/en/news/296347598.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**